Dumping Syndrome Clinical Trial
Official title:
The Effect of Fat Supplementation on the Appearance of Symptoms Associated With Dumping Syndrome in Patients Undergone Bariatric Surgery
The purpose of the study is the investigation of the effect of fat supplement on gastric emptying rate and the appearance of symptoms of Dumping Syndrome in patients who have undergone gastrointestinal- duodenal surgery. Patients who have undergone bariatric surgery have been examined for the presence of the Dumping syndrome, with glucose measurements, the Sigstad's questionnaire and questionnaire of Arts. Patients diagnosed positive, reiterated the examination process in a second meeting consuming an extra fat supplement. The data obtained on the different appointments were compared between the two groups in a cross over design.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05759689 -
Fat Supplementation on Dumping Syndrome Related Symptoms After Gastric Surgery
|
N/A | |
Recruiting |
NCT00543179 -
Treatment of the Dumping Syndrome With Lanreotide Autogel®
|
Phase 4 | |
Not yet recruiting |
NCT04522193 -
Dumping Syndrome and Esophageal Atresia
|
N/A | |
Completed |
NCT02891330 -
Impact of an Educational Personalized Clinical Support Device Preventive and a Referent Nurse in Surgery for Obesity
|
N/A | |
Completed |
NCT02525705 -
Dumping Syndrome After Operation of Esophageal Atresia Type III
|
N/A | |
Completed |
NCT01794793 -
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
|
Phase 4 | |
Completed |
NCT03734627 -
Gastrointestinal Nutrient Transit and Enteroendocrine Function After Upper Gastrointestinal Surgery
|
||
Terminated |
NCT02836353 -
Metabolic Consequences of Gastrointestinal Surgery
|
N/A | |
Completed |
NCT05057819 -
Investigating the Impact of the SGLT2 Inhibitor Empagliflozin on Postprandial Hypoglycaemia After Gastric Bypass
|
Phase 4 | |
Completed |
NCT02971631 -
Gastrectomy, Eating Behaviour and GLP-1
|
N/A | |
Completed |
NCT01923649 -
SOMATULINE Autogel 90 mg IN DUMPING SYNDROME
|
Phase 2 |